Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.

Jarrad AM, Ang CW, Debnath A, Hahn HJ, Woods K, Tan L, Sykes ML, Jones AJ, Pelingon R, Butler MS, Avery VM, West NP, Karoli T, Blaskovich MAT, Cooper MA.

J Med Chem. 2018 Dec 27;61(24):11349-11371. doi: 10.1021/acs.jmedchem.8b01578. Epub 2018 Dec 11.

2.

Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.

Jarrad AM, Debnath A, Miyamoto Y, Hansford KA, Pelingon R, Butler MS, Bains T, Karoli T, Blaskovich MA, Eckmann L, Cooper MA.

Eur J Med Chem. 2016 Sep 14;120:353-62. doi: 10.1016/j.ejmech.2016.04.064. Epub 2016 Apr 27.

3.

New synthesis and antiparasitic activity of model 5-aryl-1-methyl-4-nitroimidazoles.

Saadeh HA, Mosleh IM, El-Abadelah MM.

Molecules. 2009 Jul 27;14(8):2758-67. doi: 10.3390/molecules14082758.

4.

Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Rakesh, Bruhn DF, Scherman MS, Singh AP, Yang L, Liu J, Lenaerts AJ, Lee RE.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):388-391. doi: 10.1016/j.bmcl.2015.12.002. Epub 2015 Dec 7.

5.

Hsp90 inhibitors as new leads to target parasitic diarrheal diseases.

Debnath A, Shahinas D, Bryant C, Hirata K, Miyamoto Y, Hwang G, Gut J, Renslo AR, Pillai DR, Eckmann L, Reed SL, McKerrow JH.

Antimicrob Agents Chemother. 2014 Jul;58(7):4138-44. doi: 10.1128/AAC.02576-14. Epub 2014 May 12.

6.

Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri.

Bashyal B, Li L, Bains T, Debnath A, LaBarbera DV.

PLoS Negl Trop Dis. 2017 Aug 9;11(8):e0005832. doi: 10.1371/journal.pntd.0005832. eCollection 2017 Aug.

7.

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.

Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA.

ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.

8.

Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp.

Upcroft JA, Campbell RW, Benakli K, Upcroft P, Vanelle P.

Antimicrob Agents Chemother. 1999 Jan;43(1):73-6.

9.

Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

Palmer BD, Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA, Thompson AM.

J Med Chem. 2015 Apr 9;58(7):3036-59. doi: 10.1021/jm501608q. Epub 2015 Mar 27.

PMID:
25781074
10.

Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.

Kim P, Zhang L, Manjunatha UH, Singh R, Patel S, Jiricek J, Keller TH, Boshoff HI, Barry CE 3rd, Dowd CS.

J Med Chem. 2009 Mar 12;52(5):1317-28. doi: 10.1021/jm801246z.

11.

Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.

Thompson AM, O'Connor PD, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Martin D, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA.

J Med Chem. 2016 Mar 24;59(6):2530-50. doi: 10.1021/acs.jmedchem.5b01699. Epub 2016 Mar 8.

12.

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis.

Fairlamb AH, Patterson S.

Curr Med Chem. 2018 Apr 26. doi: 10.2174/0929867325666180426164352. [Epub ahead of print]

PMID:
29701144
13.

Synthesis, structure and biological evaluation of novel bicyclic nitroimidazole derivatives.

Zaprutko L, Zwawiak J, Augustynowicz-Kopeć E, Zwolska Z, Bartoszak-Adamska E, Nowicki W.

Arch Pharm (Weinheim). 2012 Jun;345(6):463-7. doi: 10.1002/ardp.201100379. Epub 2012 Jan 20.

PMID:
22266946
14.

Nitroimidazole drugs vary in their mode of action in the human parasite Giardia lamblia.

Leitsch D, Schlosser S, Burgess A, Duchêne M.

Int J Parasitol Drugs Drug Resist. 2012 May 12;2:166-70. doi: 10.1016/j.ijpddr.2012.04.002. eCollection 2012 Dec.

15.

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).

Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.

Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3. Review.

PMID:
30029909
16.

In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.

Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG.

Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14. Epub 2014 Oct 20.

17.

Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.

Kour G, Kumar A, Singh PP, Sharma S, Bhagat A, Vishwakarma RA, Ahmed Z.

Pulm Pharmacol Ther. 2016 Oct;40:44-51. doi: 10.1016/j.pupt.2016.06.009. Epub 2016 Jul 25.

PMID:
27457685
18.

Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia.

Valdez CA, Tripp JC, Miyamoto Y, Kalisiak J, Hruz P, Andersen YS, Brown SE, Kangas K, Arzu LV, Davids BJ, Gillin FD, Upcroft JA, Upcroft P, Fokin VV, Smith DK, Sharpless KB, Eckmann L.

J Med Chem. 2009 Jul 9;52(13):4038-53. doi: 10.1021/jm900356n.

19.

[Clinical and therapeutic study of a group of 217 patients with intestinal giardiasis and amebiasis].

Degrémont A, Stürchler D, Wolfensberger E, Osterwalder B.

Schweiz Med Wochenschr. 1981 Dec 26;111(52):2039-46. French.

PMID:
6276972
20.

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons FR, Auer JL, Osuna-Cabello M, Read KD, Fairlamb AH.

Elife. 2016 May 24;5. pii: e09744. doi: 10.7554/eLife.09744.

Supplemental Content

Support Center